23
total announcements
534920.BO · 15 min delayed
iSERA Lifesciences Ltd
iSERA Lifesciences Ltd has submitted revised un-audited financial results for the half year ended September 2026, as per SEBI regulations.
iSERA Lifesciences Ltd
iSERA Lifesciences Ltd has submitted a non-applicability of Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 30th September, 2026, citing Paid-up Equity Share Capital and Net Worth less than Rs. 10 Crore and Rs. 25 Crore respectively.
iSERA Lifesciences Ltd
iSERA Lifesciences Ltd has submitted its un-audited financial results for the quarter and half-year ended September 2026, which were approved by the Board of Directors. The results were reviewed by the independent auditor GMKS & Co, who found no material misstatements.
iSERA Lifesciences Ltd
iSERA Lifesciences Ltd has announced its un-audited financial results for the quarter and half year ended September 30, 2026, which were approved by the Board of Directors. The company's independent auditor has conducted a limited review and found no material misstatements in the financial results.
iSERA Lifesciences Ltd
iSERA Lifesciences Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 04/11/2026 to consider and approve the Un-Audited Financial Results for the quarter and half year ended on September 30, 2026.
iSERA Lifesciences Ltd
iSERA Lifesciences Ltd submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming compliance for the quarter and half year ended September 30, 2026.
iSERA Lifesciences Ltd
iSERA Lifesciences Ltd has made a preferential allotment of equity shares on a share swap basis, resulting in the acquisition of shares by various individuals. The allottees include promoters, members of the promoter group, and designated persons. The company has disclosed the details of the acquisition under Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015.
iSERA Lifesciences Ltd
iSERA Lifesciences Ltd's promoter, Archana Kakasaheb Lonkar, has submitted a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, regarding a change in her shareholding in the company due to the allotment of equity shares under a preferential allotment (share swap) by the board of directors on October 01, 2026.
iSERA Lifesciences Ltd
iSERA Lifesciences Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nandkumar Kadam.
iSERA Lifesciences Ltd
iSERA Lifesciences Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Dhairyasheel Yadav.
iSERA Lifesciences Ltd
iSERA Lifesciences Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sumeet Dhanraj Garad, indicating a potential change in control or significant stake acquisition.
iSERA Lifesciences Ltd
iSERA Lifesciences Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pratap Dadasaheb Deshmukh & PACs.
iSERA Lifesciences Ltd
iSERA Lifesciences Ltd has approved the allotment of 1,61,82,800 equity shares at Rs. 48.20 per share on a preferential basis to promoters and non-promoters.
iSERA Lifesciences Ltd
iSERA Lifesciences Ltd has approved the allotment of 1,61,82,800 equity shares at Rs. 48.20 per share on a preferential basis to promoters and non-promoters.
iSERA Lifesciences Ltd
iSERA Lifesciences Ltd has submitted the Consolidated Scrutinizer's Report on E-voting during its Annual General Meeting, confirming that two resolutions were passed with the requisite majority.
iSERA Lifesciences Ltd
iSERA Lifesciences Ltd held its 34th Annual General Meeting on September 29, 2026, via video conferencing, where 47 members attended and passed two ordinary resolutions, including the re-appointment of a director and the adoption of audited financial statements for the year ended March 31, 2026.
iSERA Lifesciences Ltd
iSERA Lifesciences Ltd has announced the closure of its trading window for all designated persons from October 01, 2026, until 48 hours after the announcement of its un-audited financial results for the quarter and half-year ended September 30, 2026.
iSERA Lifesciences Ltd
iSERA Lifesciences Ltd has filed a newspaper publication with the BSE regarding its 34th Annual General Meeting to be held on September 29, 2026, through video conferencing.
iSERA Lifesciences Ltd
iSERA Lifesciences Ltd has informed about the outcome of its Board Meeting held on September 1, 2026, where the Board approved the notice for the 34th Annual General Meeting, audited standalone financial statements for FY 2025-26, and the Annual Report for FY 2025-26.
iSERA Lifesciences Ltd
iSERA Lifesciences Ltd has submitted a monitoring agency report for the utilization of proceeds of its rights issue for the quarter ended June 30, 2026, indicating no deviation from the objects of the issue.